Trial Profile
A study of Sirolimus in patients with multidrug‐resistant Kasabach–Merritt phenomenon (KMP)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Apr 2018
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Kasabach-Merritt syndrome
- Focus Adverse reactions; Therapeutic Use
- 16 Apr 2018 New trial record